Natco Pharma is deepening its investment in clinical-stage biotechnology company eGenesis, increasing its planned investment through subsidiaries to $16.7 million from the earlier announced $14 million.

Under the revised investment plan, Natco Pharma’s Canadian subsidiary will invest $13.7 million, while Natco Pharma USA LLC will contribute $3 million. On completion of the transaction, Natco’s total investment in eGenesis will rise to $24.7 million.

Natco, through its Canadian subsidiary, had in 2024 invested $8 million in eGenesis, which is developing porcine solid organ donors using its multiplex gene-editing and genome-engineering platform, with the aim of addressing the shortage of human organs available for patients suffering from organ failure.

The company is currently advancing programmes focused on kidney transplantation, acute liver failure and heart transplantation. In March 2024, eGenesis achieved a milestone by announcing the world’s first transplant of a genetically modified pig kidney into a living human patient. The procedure was conducted under the U.S. Food and Drug Administration’s Expanded Access pathway.

The company subsequently performed pig kidney transplants in two additional patients, with Natco stating that the outcomes so far have been “exceptionally positive”.

Drugmaker Natco Pharma’s June quarter consolidated net profit slumped 57% year-on-year (YoY) to ₹206.5 crore on the back of lower sales of generic cancer drug Lenalidomide.

The profit came on a nearly 43% YoY dip in total revenue to ₹794.4 crore, largely attributable to lower sales earnings from Lenalidomide — generic of once blockbuster cancer drug Revlimid. Growth in the base business helped partially offset the drop, the company said on Friday.

Natco Pharma shares ended 5.23% lower on the BSE at ₹902.40 apiece.

International formulations, including profit share and subsidiaries, declined to ₹477.1 crore against ₹1,120.9 crore the previous year period, showed the segmental revenue numbers of the company for the quarter.

Revenues from active pharmaceutical ingredients (API) stood at ₹66.7 crore compared to ₹52.6 crore the corresponding period of FY26); domestic pharmaceutical formulations ₹136.4 crore (₹107 crore); and crop health sciences ₹40.8 crore (₹34.7 crore) .

However, other operating and non-operating income declined marginally to ₹73.4 crore (₹75.4 crore).

Revenue of associate company Adcock Ingram Holdings, South Africa, was ₹1,582.8 crore and profit after tax ₹242.2 crore. Natco’s share of profit (based on the 35.75% holding as on June 30) stood at ₹84.3 crore. In July, Natco announced the acquisition of an additional 13.25% stake in Adcock Ingram Holding taking it stake to 49%.

₹1.5 interim dividend

Natco Board has declared an interim dividend of ₹1.5 per equity share of ₹2 each. The record date has been fixed as August 20 and the payment of the interim dividend will start from August 26.

Hyderabad-based Indian multinational pharmaceutical and biotechnology company Natco Pharma’s shares were in the spotlight on Monday after it received tentative approval from the U.S. Food and Drug Administration (FDA) for Olaparib, 100 mg, and 150 mg, which are bioequivalent to AstraZeneca Pharmaceuticals’ referenced drug Lynparza used in the treatment of certain types of cancer.

The shares of the generic drugmaker touched more than 4% intra-day before ending the day less than 1% higher at Rs.950.55 each.

On Saturday, announcing the U.S. FDA approval, Natco Pharma said it would be manufacturing Olaparib tablets while its partner Alembic Pharmaceuticals would be distributing the product in the U.S. Olaparib tablets had estimated sales of around $1.4 billion in the U.S. for 12 months ending March 2026 as per industry sales data. The Para IV litigation, a statutory mechanism to resolve drug patent disputes, is on-going, it said.

Natco Pharma’s active pharmaceutical ingredients unit in Chennai has received seven observations from the U.S. Food and Drug Administration.

The U.S. FDA had conducted an inspection at the API manufacturing plant in Manali, Chennai, from November 17-21. On conclusion, of the inspection, the company received seven observations in the Form-483, the generic drugmaker said on Friday (November 21, 2025).

The company believes the observations are procedural in nature and is confident to address them comprehensively, Natco Pharma said, reaffirming commitment to being cGMP compliant and supplying high-quality products.

Natco Pharma has launched Bosentan tablets for oral suspension, 32mg, a generic version of Actelion Pharmaceuticals’ Tracleer in the U.S.

It holds the first-to-file status for this product and will have 180-day generic drug exclusivity, Natco said on Wednesday (August 20, 2025. Lupin is its marketing partner for the product.

Bosentan TFOS, 32mg, had estimated sales of $10 million in the U.S. for 12 months ending June’25, the Hyderabad-based company said citing industry sales data. The drug is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in paediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance, which is expected to result in an improvement in exercise ability.

Generic drugmaker Natco Pharma reported consolidated net profit for the June quarter declined more than 28% to ₹480.3 crore compared to ₹668.5 crore a year earlier amid pricing pressure in the key U.S. market and higher research and development expenditure.

The lower net profit came on a total revenue that dipped 1.42% to ₹1,390.6 crore (₹1,410.7 crore). During the quarter the business faced pricing pressure in the U.S. product portfolio and the company incurred increased R&D expenses on account of high value projects, Natco Pharma said.

₹2 interim dividend

The company has declared an interim dividend of ₹2 per equity share (of ₹2 each) for the first quarter.

Segmental revenue breakup showed formulations export declined, in the first quarter, to ₹1,126.5 crore (₹1,210.1 crore). Revenue from active pharmaceutical ingredients (API) increased to ₹52.6 crore (₹39.2 crore), while that from domestic formulations to ₹107 crore (₹102.2 crore). Crop Health Sciences revenue increased to ₹34.7 crore (₹15.6 crore).

Natco Pharma has made an offer to acquire nearly 36% stake in South African pharmaceutical company Adcock Ingram Holdings (AIHL) for $226 million (around ₹2,000 crore).

The proposal to acquire the stake from minority shareholders in an all cash deal is a strategic investment aimed at to expanding geographic footprint in South Africa, Natco said on Wednesday. Founded in 1890, AIHL has a diverse product portfolio, from generic and branded formulations, critical-care hospital products to consumer and home-care products. It operates across four segments -prescription, consumer, OTC and hospitals.

The acquisition is expected to be completed by 2025. Post-acquisition, AIHL will continue to operate as a private South African business with Bidvest holding 64.25% and Natco 35.75%, including a prior held 0.80% stake, in the company. Post-transaction, Natco will consolidate 35.75% of AIHL net profits in its financial results. AIHL clocked revenue of $536 million in the financial year June 2024 and profit after tax of $45 million.

“Adcock Ingram is a respectable pharmaceutical company with well-recognised brands and products and maintains a leading position in the South African pharmaceutical market. The proposed transaction will provide Natco Pharma with a well-established entry into the Southern African market. It will also allow us to tap into new revenue streams and expand our footprint in one of the largest and growing emerging markets, while providing a gateway to the African continent,” CEO and Vice-Chairman Rajeev Nannapaneni said.

Besides the acquisition, Natco Pharma Board also approved a proposal to incorporate a wholly owned subsidiary in South Africa with an investment of up to Rs.2,100 crore by this year to enter new geographies for growth and increased profitability. It also approved a proposal to liquidate wholly owned subsidiary Time Cap Overseas (TCOL), and directly hold the investment in step down subsidiary NatcoFarma do Brasil.

Natco shares closed 2.01% higher at ₹1,034.75 apiece on the BSE.